BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 37864958)

  • 1. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
    Zhu X
    N Engl J Med; 2018 Dec; 379(24):2379-2380. PubMed ID: 30592586
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
    Fozza C
    N Engl J Med; 2018 Dec; 379(24):2379. PubMed ID: 30592585
    [No Abstract]   [Full Text] [Related]  

  • 3. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
    Konuma T; Kato S; Ishii H; Oiwa-Monna M; Asano S; Tojo A; Takahashi S
    Leuk Res; 2015 Jun; 39(6):625-31. PubMed ID: 25888304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
    Notarantonio AB; Roth-Guépin G; Bonmati C; Divoux M; Kicki C; Pagliuca S; Campidelli A; Rubio MT; D'Aveni-Piney M
    Leuk Res; 2023 Dec; 135():107405. PubMed ID: 37864958
    [No Abstract]   [Full Text] [Related]  

  • 6. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
    Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
    Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPX-351 (vyxeos) in AML.
    Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
    Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.